Dupilumab for the treatment of atopic dermatitis

Dupilumab (Dupixent) is a new monoclonal antibody treatment licensed for use in adults with moderate to severe atopic dermatitis (eczema) who are candidates for systemic therapy. This article discusses its properties, efficacy and side‐effects.